Telix reports positive Phase 3 Part 1 results for prostate cancer drug

March 9, 2026 7:20 PM

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found